Skip to content
22 Aug 2023

Reckitt research on ‘Ibuprofen, other NSAIDs and COVID‑19’ published in Inflammopharmacology

Our Global Medical Sciences team has authored the most comprehensive and up to date review.

ImpactBrandsNewsPress Release
1 minute read
Reckitt research on ‘Ibuprofen, other NSAIDs and COVID‑19’ published in Inflammopharmacology

Our publication, in the peer reviewed academic journal Inflammopharmacology, reviews all the key literature in the field, including our own groundbreaking research, concluding that the scientific evidence overwhelmingly refutes the speculation that ibuprofen worsens outcomes in COVID-19.

“At Reckitt, we know self-care is at the heart of health and wellbeing. For the public to benefit from self-care, they need to have trust in the available treatment options and access to appropriate, accurate information. We hope that in publishing this and other scientific research we’re able to increase understanding and ensure people feel equipped to look after themselves and their families.”

Dr Bruce Charlesworth

Chief Medical Officer, Reckitt

Share to